YourChoice Therapeutics

YourChoice Therapeutics

YourChoice Therapeutics is a biotechnology company founded in 2018 is developing contraceptives for men and women. The technology for their non-hormonal contraceptive products arose from research at the University of California, Berkeley.

YourChoice Therapeutics is a biotechnology company that was one of the 2018 CITRIS Foundry Startups founded by Akash Bakshi, Nadja Mannowetz, and Polina Lishko.

One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

Funding

Seed

On January 1, 2019 YourChoice Therapeutics completed a seed funding round with $550,000 in funding from Y Combinator.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Akash Bakshi

Co-Founder, CEO

Nadja Mannowetz

Co-Founder, CSO

POLINA LISHKO

Founder, Consultant

Further reading

Title
Author
Link
Type
Date

Regulation of the sperm calcium channel CatSper by endogenous steroids and plant triterpenoids

Pnas

Web

YourChoice Therapeutics is developing unisex, non-hormonal birth control

Kate Clark

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Kate Clark
March 14, 2019
TechCrunch
The latest Y Combinator-backed startup is targeting the $36 billion contraceptive market.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.